Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Investigative Radiology|February 2, 2023
Multimodal In Vivo Tracking of Chimeric Antigen Receptor T Cells in Preclinical Glioblastoma ModelsWei Emma Wu, Edwin Chang, Linchun Jin, et al.
British Journal of Cancer|October 14, 2024
Identification of a 5-gene signature panel for the prediction of prostate cancer progressionMichelle Shen, Fernando García-Marqués, Arvind Muruganantham, et al.
Cancer Research|September 5, 2025
Extracellular Domain Shedding of TROP2 Activates EGFR Signaling to Drive Prostate Cancer MetastasisShiqin Liu, En-Chi Hsu, Merve Aslan, et al.
The Lancet. Global Health|May 13, 2022
What next? Expanding our view of city planning and global health, and implementing and monitoring evidence-informed policyBillie Giles-Corti, Anne Vernez Moudon, Melanie Lowe, et al.
Environment and Planning. B, Urban Analytics and City Science|April 1, 2026
Global Healthy and Sustainable City Indicators: Collaborative development of an open science toolkit for calculating and reporting on urban indicators internationallyCarl Higgs, Melanie Lowe, Billie Giles-Corti, et al.
The Lancet. Global Health|May 13, 2022
Determining thresholds for spatial urban design and transport features that support walking to create healthy and sustainable cities: findings from the IPEN Adult studyEster Cerin, James F Sallis, Deborah Salvo, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 15, 2020
Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1En-Chi Hsu, Meghan A Rice, Abel Bermudez, et al.
Scientific Reports|January 4, 2024
High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarkerShiqin Liu, Sarah J Hawley, Christian A Kunder, et al.
Science (New York, N.Y.)|March 19, 2026
Overcoming T cell tolerance to tumor self-antigens through catch-bond engineeringXiaojing Chen, Zhiyuan Mao, E Motunrayo Kolawole, et al.
Cell Reports. Medicine|March 4, 2022
SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancerMeghan A Rice, Vineet Kumar, Dhanir Tailor, et al.
Pageof 8